Back
Byline Bancorp Vs. Ultragenyx Pharmaceutical Industry Stock Comparison
Buy
64
BY
Byline Bancorp
Last Price:
23.18
Seasonality Move:
-1.65%
Sell
44
RARE
Ultragenyx Pharmaceutical
Last Price:
41.40
Seasonality Move:
-0.9%
Buy
64
Byline Bancorp (BY)
is a Buy
Is Byline Bancorp a Buy, Sell or Hold?
- The current Byline Bancorp [BY] share price is $22.98. The Score for BY is 64, which is 28% above its historic median score of 50, and infers lower risk than normal.
- BY is currently trading in the 60-70% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a higher than normal reading, suggesting risk levels may be somewhat lower than normal.
Sell
44
Ultragenyx Pharmaceutical (RARE)
is a Sell
Is Ultragenyx Pharmaceutical a Buy, Sell or Hold?
- The current Ultragenyx Pharmaceutical [RARE] share price is $40.50. The Score for RARE is 44, which is 12% below its historic median score of 50, and infers higher risk than normal.
- RARE is currently trading in the 40-50% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.
BY Stock Price Chart
What is Byline Bancorp's stock price today?
-
The Byline Bancorp share price today is $22.98
Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and BY is experiencing buying pressure, which is a positive indicator for future bullish movement.
RARE Stock Price Chart
What is Ultragenyx Pharmaceutical's stock price today?
-
The Ultragenyx Pharmaceutical share price today is $40.50
The current trend is relatively stagnant and RARE is experiencing slight buying pressure.
BY Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | 0.02 | Buy |
| Relative Strength Index (14 RSI): | 54.69 | Buy |
| Chaikin Money Flow: | 96572 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (22.43 - 23.19) | Buy |
| Bollinger Bands (100): | (20.52 - 22.84) | Buy |
RARE Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | -0.6 | Sell |
| Relative Strength Index (14 RSI): | 49.22 | Sell |
| Chaikin Money Flow: | 494801 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (38.79 - 41.97) | Buy |
| Bollinger Bands (100): | (40.81 - 48.79) | Sell |
BY Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 22.73 | Buy |
| 20-day SMA: | 22.66 | Buy |
| 50-day SMA: | 22.56 | Buy |
| 200-day SMA: | 21.36 | Buy |
| 8-day EMA: | 22.75 | Buy |
| 20-day EMA: | 22.74 | Buy |
| 50-day EMA: | 22.49 | Buy |
| 200-day EMA: | 21.69 | Buy |
RARE Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 39.2 | Buy |
| 20-day SMA: | 40.42 | Buy |
| 50-day SMA: | 41.53 | Sell |
| 200-day SMA: | 42.45 | Sell |
| 8-day EMA: | 39.89 | Buy |
| 20-day EMA: | 40.39 | Buy |
| 50-day EMA: | 41.79 | Sell |
| 200-day EMA: | 43.35 | Sell |
Byline Bancorp Earnings Growth & BY Earnings Dates
- Analysts estimate an earnings decrease this quarter of $0.01 per share, a decrease next quarter of $0.01 per share, a decrease this year of $0.21 per share, and a decrease next year of $0.07 per share.
Ultragenyx Pharmaceutical Earnings Growth & RARE Earnings Dates
- Analysts estimate an earnings increase this quarter of $0.51 per share, an increase next quarter of $0.03 per share, an increase this year of $0.94 per share, and an increase next year of $1.06 per share.
Byline Bancorp Technical Analysis
| Jun 12 | Jun 13 | Jun 14 | Jun 17 | Jun 18 | Jun 20 | Jun 21 | Jun 24 | Jun 25 | Jun 26 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun | ||||||||||
| 12 | 13 | 14 | 17 | 18 | 20 | 21 | 24 | 25 | 26 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||
Ultragenyx Pharmaceutical Technical Analysis
| Jun 12 | Jun 13 | Jun 14 | Jun 17 | Jun 18 | Jun 20 | Jun 21 | Jun 24 | Jun 25 | Jun 26 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun | ||||||||||
| 12 | 13 | 14 | 17 | 18 | 20 | 21 | 24 | 25 | 26 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||